Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-26-000904
Filing Date
2026-01-02
Accepted
2026-01-02 16:01:35
Documents
15
Effectiveness Date
2026-01-02

Document Format Files

Seq Description Document Type Size
1 S-8 d11495ds8.htm S-8 33993
2 EX-5.1 d11495dex51.htm EX-5.1 5389
3 EX-23.1 d11495dex231.htm EX-23.1 1735
4 EX-23.2 d11495dex232.htm EX-23.2 2038
5 EX-FILING FEES d11495dexfilingfees.htm   iXBRL EX-FILING FEES 17022
  Complete submission text file 0001193125-26-000904.txt   190314

Data Files

Seq Description Document Type Size
17 EXTRACTED XBRL INSTANCE DOCUMENT d11495dexfilingfees_htm.xml XML 8409
Mailing Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080
Business Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080 857 702 0377
BridgeBio Oncology Therapeutics, Inc. (Filer) CIK: 0001869105 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-292555 | Film No.: 26502316
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)